<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36895908</PMID><DateRevised><Year>2023</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Incidence of Guillain-Barr&#xe9; syndrome in South Korea during the early COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>1125455</StartPage><MedlinePgn>1125455</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1125455</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2023.1125455</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">Guillain-Barr&#xe9; syndrome (GBS) is an immune-mediated polyradiculoneuropathy, often triggered by infection. We aimed to investigate how the incidence of GBS changed in the early stages of the coronavirus 2019 (COVID-19) pandemic when nationwide infections declined due to non-pharmaceutical interventions.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a nationwide population-based retrospective GBS cohort study using data from the Health Insurance Review and Assessment Service of Korea. Patients with new-onset GBS were defined as those who were first hospitalized between 1 January 2016 and 31 December 2020 with an International Classification of Disease, 10th Revision code, for GBS (G61.0) as a primary diagnosis. The incidence of GBS in the pre-pandemic years (2016-2019) was compared with that in the first pandemic year (2020). Nationwide epidemiological data for infections were collected from the national infectious disease surveillance system. A correlation analysis was performed to determine the incidence of GBS and nationwide trends of various infections.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Overall, 3,637 new-onset GBS cases were identified. The age-standardized incidence of GBS in the first pandemic year was 1.10 (95% confidence interval, 1.01-1.19) per 100,000 persons. Compared to the first pandemic year, the incidence of GBS during the pre-pandemic years (1.33-1.68/100,000 persons/year) was significantly higher, with incidence rate ratios of 1.21-1.53 (<i>P</i> &lt; 0.001). Nationwide cases of upper respiratory viral infections were significantly reduced in the first pandemic year; however, <i>Campylobacter</i> infections peaked in the summer of the pandemic. The nationwide epidemiology of parainfluenza virus, enterovirus, and <i>Campylobacter</i> infections correlated positively with GBS incidence.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The overall GBS incidence decreased in the early stages of the COVID-19 pandemic, which can be attributed to the dramatic reduction in viral illnesses due to public measures.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Choi, Hwang, Lim and Chae.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sun Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Junho</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Byung Chan</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Soo Ahn</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Front Neurol. 2023 Apr 11;14:1184177. doi: 10.3389/fneur.2023.1184177</RefSource><PMID Version="1">37114228</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Campylobacter</Keyword><Keyword MajorTopicYN="N">Guillain-Barr&#xe9; syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">nationwide infection</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>10</Day><Hour>2</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36895908</ArticleId><ArticleId IdType="pmc">PMC9989167</ArticleId><ArticleId IdType="doi">10.3389/fneur.2023.1125455</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. . Diagnosis and management of Guillain-Barr&#xe9; syndrome in ten steps. Nat Rev Neurol. (2019) 15:671&#x2013;83. 10.1038/s41582-019-0250-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0250-9</ArticleId><ArticleId IdType="pmc">PMC6821638</ArticleId><ArticleId IdType="pubmed">31541214</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs BC, Rothbarth PH, van der Mech&#xe9; FG, Herbrink P, Schmitz P, de Klerk MA, et al. . The spectrum of antecedent infections in Guillain-Barr&#xe9; syndrome: a case-control study. Neurology. (1998) 51:1110&#x2013;5. 10.1212/WNL.51.4.1110</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.4.1110</ArticleId><ArticleId IdType="pubmed">9781538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao-Lormeau VM, Blake A, Mons S, Last&#xe8;re S, Roche C, Vanhomwegen J, et al. . Guillain-Barr&#xe9; syndrome outbreak associated with Zika virus infection in French polynesia: a case-control study. Lancet. (2016) 387:1531&#x2013;9. 10.1016/S0140-6736(16)00562-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00562-6</ArticleId><ArticleId IdType="pmc">PMC5444521</ArticleId><ArticleId IdType="pubmed">26948433</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos AP, Leonhard SE, Halstead SK, Cuba MA, Casta&#xf1;eda CC, Dioses JA, et al. . Guillain-Barr&#xe9; syndrome outbreak in Peru 2019 associated with Campylobacter jejuni infection. Neurol Neuroimmunol Neuroinflamm. (2021) 8:e952. 10.1212/NXI.0000000000000952</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000952</ArticleId><ArticleId IdType="pmc">PMC8057064</ArticleId><ArticleId IdType="pubmed">33547152</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, et al. . Guillain-Barr&#xe9; syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies Brain. (1995) 118:597&#x2013;605. 10.1093/brain/118.3.597</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.3.597</ArticleId><ArticleId IdType="pubmed">7600081</ArticleId></ArticleIdList></Reference><Reference><Citation>Huizinga R, van den Berg B, van Rijs W, Tio-Gillen AP, Fokkink W, Bakker-Jonges LE, et al. . Innate immunity to Campylobacter jejuni in Guillain-Barre syndrome. Ann Neurol. (2015) 78:343&#x2013;54. 10.1002/ana.24442</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24442</ArticleId><ArticleId IdType="pubmed">26017721</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatu L, Nono S, Gr&#xe1;cio S, Ko&#xe7;er S. Guillain-Barr&#xe9; syndrome in the COVID-19 era: another occasional cluster? J Neurol. (2021) 268:1198&#x2013;200. 10.1007/s00415-020-10005-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10005-3</ArticleId><ArticleId IdType="pmc">PMC7309426</ArticleId><ArticleId IdType="pubmed">32577868</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigli GL, Bax F, Marini A, Pellitteri G, Scalise A, Surcinelli A, et al. . Guillain-Barr&#xe9; syndrome in the COVID-19 era: just an occasional cluster? J Neurol. (2021) 268:1195&#x2013;7. 10.1007/s00415-020-09911-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09911-3</ArticleId><ArticleId IdType="pmc">PMC7236438</ArticleId><ArticleId IdType="pubmed">32430572</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosto M, Cotti Piccinelli S, Gazzina S, Foresti C, Frigeni B, Cristina M, et al. . Guillain-Barr&#xe9; syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J Neurol Neurosurg Psychiatry. (2021) 92:751&#x2013;6. 10.1136/jnnp-2020-324837</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324837</ArticleId><ArticleId IdType="pubmed">33158914</ArticleId></ArticleIdList></Reference><Reference><Citation>Fragiel M, Mir&#xf3; &#xd2;, Llorens P, Jim&#xe9;nez S, Pi&#xf1;era P, et al. . Incidence, clinical, risk factors and outcomes of Guillain-Barr&#xe9; in COVID-19. Ann Neurol. (2021) 89:598&#x2013;603. 10.1002/ana.25987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25987</ArticleId><ArticleId IdType="pubmed">33295021</ArticleId></ArticleIdList></Reference><Reference><Citation>Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Giovanna Cuzzoni M, et al. . Guillain-Barr&#xe9; syndrome associated with SARS-CoV-2. N Engl J Med. (2020) 382:2574&#x2013;6. 10.1056/NEJMc2009191</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2009191</ArticleId><ArticleId IdType="pmc">PMC7182017</ArticleId><ArticleId IdType="pubmed">32302082</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barr&#xe9; syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol. (2020) 19:383&#x2013;4. 10.1016/S1474-4422(20)30109-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30109-5</ArticleId><ArticleId IdType="pmc">PMC7176927</ArticleId><ArticleId IdType="pubmed">32246917</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C, et al. . Prevalence, clinical characteristics and outcomes of Guillain-Barr&#xe9; syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. (2021) 28:3517&#x2013;29. 10.1111/ene.14860</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14860</ArticleId><ArticleId IdType="pmc">PMC8250909</ArticleId><ArticleId IdType="pubmed">33837630</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K, Jung J, Hong J, Kim M, Ahn JG, Kim J, et al. . Impact of nonpharmaceutical interventions on the incidence of respiratory infections during the coronavirus disease 2019 (COVID-19) outbreak in Korea: a nationwide surveillance study. Clin Infect Dis. (2021) 72:e184&#x2013;91. 10.1093/cid/ciaa1682</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1682</ArticleId><ArticleId IdType="pmc">PMC7665442</ArticleId><ArticleId IdType="pubmed">33150393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SY, Park JY, Lim IS, Chae SA, Yun SW, Lee NM, et al. . Changes in the occurrence of gastrointestinal infections after COVID-19 in Korea. J Korean Med Sci. (2021) 36:e180. 10.3346/jkms.2021.36.e180</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2021.36.e180</ArticleId><ArticleId IdType="pmc">PMC8216988</ArticleId><ArticleId IdType="pubmed">34155841</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. (2017) 32:718&#x2013;28. 10.3346/jkms.2017.32.5.718</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.5.718</ArticleId><ArticleId IdType="pmc">PMC5383602</ArticleId><ArticleId IdType="pubmed">28378543</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S, Cho E. National Infectious Diseases Surveillance data of South Korea. Epidemiol Health. (2014) 36:e2014030. 10.4178/epih/e2014030</Citation><ArticleIdList><ArticleId IdType="doi">10.4178/epih/e2014030</ArticleId><ArticleId IdType="pmc">PMC4272235</ArticleId><ArticleId IdType="pubmed">25420951</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi SW, Lee JH, Hong JM, Choi YC, Park HJ. Incidence, disability, and mortality in patients with Guillain-Barr&#xe9; syndrome in Korea: a nationwide population-based study. J Clin Neurol. (2022) 18:48&#x2013;58. 10.3988/jcn.2022.18.1.48</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2022.18.1.48</ArticleId><ArticleId IdType="pmc">PMC8762496</ArticleId><ArticleId IdType="pubmed">35021276</ArticleId></ArticleIdList></Reference><Reference><Citation>Levison LS, Thomsen RW, Markvardsen LK, Christensen DH, Sindrup SH, Andersen H. Pediatric Guillain- Barr&#xe9; syndrome in a 30-year nationwide cohort. Pediatr Neurol. (2020) 107:57&#x2013;63. 10.1016/j.pediatrneurol.2020.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.01.017</ArticleId><ArticleId IdType="pubmed">32192820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim AY, Lee H, Lee YM, Kang HY. Epidemiological features and economic burden of Guillain-Barr&#xe9; syndrome in South Korea: a nationwide population-based study. J Clin Neurol. (2021) 17:257&#x2013;64. 10.3988/jcn.2021.17.2.257</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2021.17.2.257</ArticleId><ArticleId IdType="pmc">PMC8053545</ArticleId><ArticleId IdType="pubmed">33835747</ArticleId></ArticleIdList></Reference><Reference><Citation>Keddie S, Pakpoor J, Mousele C, Pipis M, Machado PM, Foster M, et al. . Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr&#xe9; syndrome. Brain. (2021) 144:682&#x2013;93. 10.1093/brain/awaa433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa433</ArticleId><ArticleId IdType="pmc">PMC7799186</ArticleId><ArticleId IdType="pubmed">33313649</ArticleId></ArticleIdList></Reference><Reference><Citation>Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, et al. . Guillain-Barr&#xe9; syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain. (2021) 144:3392&#x2013;404. 10.1093/brain/awab279</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab279</ArticleId><ArticleId IdType="pmc">PMC8677532</ArticleId><ArticleId IdType="pubmed">34553216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Ahn E, Lee S, Lim DH, Kim A, Lee SG, et al. . Changing patterns of medical visits and factors associated with no-show in patients with rheumatoid arthritis during COVID-19 pandemic. J Korean Med Sci. (2020) 35:e423. 10.3346/jkms.2020.35.e423</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e423</ArticleId><ArticleId IdType="pmc">PMC7735912</ArticleId><ArticleId IdType="pubmed">33316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. . Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. (2021) 11:e045343. 10.1136/bmjopen-2020-045343</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045343</ArticleId><ArticleId IdType="pmc">PMC7969768</ArticleId><ArticleId IdType="pubmed">33727273</ArticleId></ArticleIdList></Reference><Reference><Citation>Byung J. Impact of the COVID-19 pandemic on the utilization of medical care services. (dissertation/master's thesis). (2021). Seoul: Seoul National University.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>